Charles River Laboratories International (NYSE:CRL) EVP Sells $65,488.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph Laplume sold 400 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $163.72, for a total value of $65,488.00. Following the sale, the executive vice president owned 23,716 shares of the company’s stock, valued at approximately $3,882,783.52. The trade was a 1.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Charles River Laboratories International Stock Performance

CRL stock traded up $0.49 on Tuesday, reaching $220.19. 42,146 shares of the company were exchanged, compared to its average volume of 765,870. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The firm has a market capitalization of $10.84 billion, a PE ratio of -140.90, a PEG ratio of 6.57 and a beta of 1.61. The stock’s fifty day moving average price is $192.82 and its 200 day moving average price is $174.70. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. During the same quarter in the prior year, the business earned $2.59 earnings per share. The firm’s revenue for the quarter was down .5% on a year-over-year basis. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Mizuho set a $215.00 price objective on Charles River Laboratories International in a report on Friday, January 9th. Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, December 15th. Robert W. Baird set a $224.00 price target on Charles River Laboratories International in a research note on Friday, January 9th. Baird R W upgraded Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Morgan Stanley set a $185.00 target price on shares of Charles River Laboratories International in a research note on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $209.46.

Hedge Funds Weigh In On Charles River Laboratories International

A number of large investors have recently modified their holdings of CRL. Ameriprise Financial Inc. lifted its holdings in Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after buying an additional 575,039 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International by 29.1% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after buying an additional 516,521 shares during the period. National Bank of Canada FI raised its position in shares of Charles River Laboratories International by 117.7% during the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after acquiring an additional 511,901 shares during the last quarter. Norges Bank acquired a new position in shares of Charles River Laboratories International during the second quarter valued at $76,952,000. Finally, Balyasny Asset Management L.P. boosted its holdings in Charles River Laboratories International by 722.5% in the second quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company’s stock valued at $65,885,000 after acquiring an additional 381,432 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.